Quotes 5-day view Delayed Nasdaq
05/10/2022
05/11/2022
05/12/2022
05/13/2022
05/16/2022
Date
38.2(c)
38.58(c)
39.04(c)
40.42(c)
41.69(c)
Last
1 163 211
1 495 897
1 009 118
1 101 626
1 318 723
Volume
+2.28% +0.99% +1.19% +3.53% +3.14% Change
Estimated financial data (e) (USD)
Sales 2022
558 M - -
Net income 2022
280 M - -
Net Debt 2022
172 M - -
P/E ratio 2022
20,4x
Yield 2022
-
Sales 2023
710 M - -
Net income 2023
379 M - -
Net cash position 2023
157 M - -
P/E ratio 2023
15,2x
Yield 2023
-
Capitalization
5 744 M 5 744 M -
EV / Sales 2022
10,6x
EV / Sales 2023
7,87x
Nbr of Employees
145
Free-Float
98,8%
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’...
Ratings of Halozyme Therapeutics, Inc.
All news about HALOZYME THERAPEUTICS, INC.
05/12 Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition MT
05/12 Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR
05/11 JMP Securities Raises Halozyme Therapeutics Price Target to $58 From $55, Maintains Mar.. MT
05/10 TRANSCRIPT : Halozyme Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022CI
05/10 HALOZYME THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio.. AQ
05/10 Halozyme Therapeutics' Q1 Non-GAAP Earnings, Revenue Rise; Issues Full Year 2022 Guidan.. MT
05/10 Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q1 Revenue $117.3M, vs. Street Est of.. MT
05/10 HALOZYME THERAPEUTICS : Q1 Earnings SnapshotAQ
05/10 Halozyme Reports First Quarter 2022 Results PR
05/10 Halozyme Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March .. CI
05/10 Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022 CI
05/06 HALOZYME THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-..AQ
05/03 Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call PR
04/26 Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares MT
04/26 Halozyme commences tender offer for all outstanding shares of common stock of antares p.. PR
News in other languages on HALOZYME THERAPEUTICS, INC.
Analyst Recommendations on HALOZYME THERAPEUTICS, INC.
Chart HALOZYME THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends HALOZYME THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Bearish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
8
Last Close Price
41,69 $
Average target price
49,13 $
Spread / Average Target
17,8%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
